|
|||||
|
|
Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor,in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate |
|
| Authors: | Mark C. Genovese Josef S. Smolen Michael E. Weinblatt Gerd R. Burmester Sebastian Meerwein Heidi S. Camp Li Wang Ahmed A. Othman Nasser Khan Aileen L. Pangan Steven Jungerwirth |
| Abstract: | |
| Keywords: | |